GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal
GSK Consumer purchases outside-of-US rights to pain-relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous electrical nerve stimulation products.
You may also be interested in...
While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.
“The present has passed us by” in using appropriate technology to provide consumers more information than on US Drug Facts labels, Pinney Associates’ Saul Shiffman says at CPHA conference.
Consumers ages 18 to 35 represent nearly half the respondents saying they use CBD-containing products for mental health; consumers 35- to 65-years-old make up the majority saying they use the products for sleep issues, according to marketing and research firm Bigeye Agency.